Back to School: How biopharma can reboot drug development. Access exclusive analysis here

LJPC reports additional LJP 394 data

La Jolla Pharmaceutical (LJPC) presented additional data from a Phase II/III study

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE